Breaking News Instant updates and real-time market news.

CVS

CVS Health

$62.07

0.47 (0.76%)

, SNY

Sanofi

$46.25

-0.37 (-0.79%)

05:38
09/30/19
09/30
05:38
09/30/19
05:38

CVS suspends sales of Zantac and other ranitidine products

CVS Health (CVS) announced Saturday that it has suspended the sale of all Zantac brand and CVS brand ranitidine products until further notice. "This action is being taken out of an abundance of caution due to a recent Product Alert from the U.S. Food and Drug Administration that ranitidine products may contain a low level of nitrosodimethylamine, which is a probable human carcinogen," the company said in a statement. Zantac is sold by (SNY) and ranitidine is an H2 blocker that is taken to provide heartburn relief. CVS Pharmacy will continue to sell other over-the-counter H2 blockers, including Pepcid, Tagamet and its respective generic equivalents, famotidine and cimetidine. Reference Link

CVS

CVS Health

$62.07

0.47 (0.76%)

SNY

Sanofi

$46.25

-0.37 (-0.79%)

  • 02

    Oct

CVS CVS Health
$62.07

0.47 (0.76%)

08/09/19
MSCO
08/09/19
NO CHANGE
Target $74
MSCO
Overweight
CVS's Q2 gives window into possible power of the enterprise, says Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser said CVS Health's Q2 results and conference call "provided a window to what the power of the enterprise could materialize into," citing improved retail comps, share gains and the company's Medicare Advantage strategies. The analyst, who thinks the company's opportunity to capture share in Medicare Advantage organically by cross-selling is underestimated by the market, keeps an Overweight rating and $74 price target on CVS shares.
08/27/19
COWN
08/27/19
NO CHANGE
Target $76
COWN
Outperform
CVS Health price target raised to $76 from $69 at Cowen
Cowen analyst Charles Ryhee raised his price target on CVS Health to $76 from $69 to reflect revised 2019 guidance. The analyst believes the 2019 guidance looks conservative and with faster synergy realization and improved 2020 selling season, the company's 2020 guidance looks achievable. Ryhee reiterated his Outperform rating on CVS Health shares.
09/11/19
DBAB
09/11/19
INITIATION
Target $91
DBAB
Buy
CVS Health initiated with a Buy at Deutsche Bank
Deutsche Bank analyst George Hill initiated CVS Health with a Buy rating and a Top Pick designation along with a price target of $91 as part of a broader research note on Healthcare Technology & Services. The analyst contends that the company is "well positioned to deliver on a vertical integration care delivery strategy", capturing market share and generating positive earnings surprises. Hill also sees the valuation of CVS shares as "highly compelling".
09/27/19
RBCM
09/27/19
INITIATION
Target $85
RBCM
Outperform
CVS Health assumed with an Outperform at RBC Capital
RBC Capital analyst Anton Hie assumed coverage of CVS Health with an Outperform rating and a price target of $59. The analyst believes that the company is "positioned to lead the transformation of healthcare delivery" using its "unique" vertically integrated assets and contends that investors underappreciate the opportunity for CVS Health amid near-term headwinds. Hie adds that the company can accelerate its earnings growth toward its long-term target in the "low double digits" by 2022, with integration synergies and "enterprise modernization" helping to deliver about $3.5B in additional operating income.
SNY Sanofi
$46.25

-0.37 (-0.79%)

09/20/19
MSCO
09/20/19
UPGRADE
MSCO
Overweight
Morgan Stanley upgrades 'defensive' Sanofi to Overweight
As previously reported, Morgan Stanley upgraded Sanofi to Overweight from Equal Weight with analyst Mark Purcell arguing that the company has the lowest risk growth outlook in European pharma given its lack of major patent cliffs and the "largely de-risked" nature of pipeline drugs in the late stages. He thinks Sanofi's defensive qualities position it as a key holding in the current environment and also believes the company's new CEO Paul Hudson has significant optionality to unlock shareholder value, Purcell tells investors. He raised his price target on Sanofi shares to EUR90 from EUR79.
09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Sanofi upgraded to Buy from Neutral at Guggenheim
09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Sanofi upgraded to Buy on Dupixent's accelerating uptake at Guggenheim
Guggenheim analyst Seamus Fernandez upgraded Sanofi (SNY) to Buy from Neutral based on his view that Dupixent's accelerating uptake across Asthma and Atopic Dermatitis, and several other indications, should drive earlier than expected profitability of the Regeneron (REGN) antibody collaboration. He also believes that emerging markets growth should help stabilize the large established products and overall diabetes franchises and thinks that vaccines business growth looks sustainable. Fernandez, who also thinks pipeline expectations seem low, set a EUR96 price target on Sanofi shares.
09/23/19
GUGG
09/23/19
UPGRADE
Target $403
GUGG
Buy
Guggenheim upgrades Regeneron to Buy, says sentiment too negative
As previously reported, Guggenheim upgraded Regeneron (REGN) to Buy from Neutral as analyst Yatin Suneja noted that Eylea has maintained its dominance in the branded anti-VEGF retinal disease market despite "stiff branded competition" from Roche's (RHHBY) Lucentis and off-label use of Roche's Avastin. Eylea's expansion into new indications has resulted in a diversified business and defensible market position, argued Suneja, who also believes the Street is substantially under-appreciating the market opportunity for Dupixent, which is expected to drive significant leverage in the Sanofi (SNY) antibody collaboration that recently became profitable. Suneja raised the price target on Regeneron shares to $403 from $355.

TODAY'S FREE FLY STORIES

ALB

Albemarle

$67.72

-0.29 (-0.43%)

05:37
11/12/19
11/12
05:37
11/12/19
05:37
Downgrade
Albemarle rating change  »

Albemarle downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.86

0.11 (0.62%)

05:36
11/12/19
11/12
05:36
11/12/19
05:36
Downgrade
Cellular Biomedicine rating change  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNIRF

Senior plc

$0.00

(0.00%)

05:36
11/12/19
11/12
05:36
11/12/19
05:36
Downgrade
Senior plc rating change  »

Senior plc downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SOLVY

Solvay

$0.00

(0.00%)

05:34
11/12/19
11/12
05:34
11/12/19
05:34
Upgrade
Solvay rating change  »

Solvay upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

BOX

Box

$16.45

-0.495 (-2.92%)

05:32
11/12/19
11/12
05:32
11/12/19
05:32
Downgrade
Box rating change  »

Box downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

CTVA

Corteva

$26.74

0.54 (2.06%)

05:30
11/12/19
11/12
05:30
11/12/19
05:30
Initiation
Corteva initiated  »

Corteva initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

IFJPY

Informa

$0.00

(0.00%)

05:30
11/12/19
11/12
05:30
11/12/19
05:30
Upgrade
Informa rating change  »

Informa upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPKFF

LPKF Laser & Electronics

$0.00

(0.00%)

05:29
11/12/19
11/12
05:29
11/12/19
05:29
Downgrade
LPKF Laser & Electronics rating change  »

LPKF Laser &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETN

Eaton

$91.87

-0.35 (-0.38%)

05:28
11/12/19
11/12
05:28
11/12/19
05:28
Downgrade
Eaton rating change  »

Eaton downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 19

    Nov

  • 19

    Nov

COVTY

Covestro

$0.00

(0.00%)

05:27
11/12/19
11/12
05:27
11/12/19
05:27
Downgrade
Covestro rating change  »

Covestro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPRUY

Kering

$0.00

(0.00%)

05:27
11/12/19
11/12
05:27
11/12/19
05:27
Upgrade
Kering rating change  »

Kering upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$16.11

-0.1 (-0.62%)

05:26
11/12/19
11/12
05:26
11/12/19
05:26
Upgrade
Fiat Chrysler rating change  »

Fiat Chrysler upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUGOY

Peugeot

$0.00

(0.00%)

05:26
11/12/19
11/12
05:26
11/12/19
05:26
Upgrade
Peugeot rating change  »

Peugeot upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAVS

Ageagle Aerial Systems

$0.42

0.0385 (10.13%)

05:25
11/12/19
11/12
05:25
11/12/19
05:25
Conference/Events
Ageagle Aerial Systems to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

NNGRY

NN Group

$0.00

(0.00%)

05:25
11/12/19
11/12
05:25
11/12/19
05:25
Downgrade
NN Group rating change  »

NN Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$17.10

-0.22 (-1.27%)

05:23
11/12/19
11/12
05:23
11/12/19
05:23
Earnings
Embraer backs FY20 revenue view of $2.5B-$2.8B »

May not compare to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PRBZF

Premium Brands

$0.00

(0.00%)

05:22
11/12/19
11/12
05:22
11/12/19
05:22
Downgrade
Premium Brands rating change  »

Premium Brands downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$17.10

-0.22 (-1.27%)

05:21
11/12/19
11/12
05:21
11/12/19
05:21
Earnings
Embraer backs FY19 revenue guidance of $5.3M-$5.7M, consensus $5.37M »

Embraer reaffirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

OZMLF

Oz Minerals

$0.00

(0.00%)

05:21
11/12/19
11/12
05:21
11/12/19
05:21
Downgrade
Oz Minerals rating change  »

Oz Minerals downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SESN

Sesen Bio

$1.14

(0.00%)

05:20
11/12/19
11/12
05:20
11/12/19
05:20
Conference/Events
Sesen Bio to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ERJ

Embraer

$17.10

-0.22 (-1.27%)

05:19
11/12/19
11/12
05:19
11/12/19
05:19
Earnings
Embraer reports Q3 EPS (26c), consensus (9c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

AAXN

Axon

$64.41

-0.95 (-1.45%)

05:18
11/12/19
11/12
05:18
11/12/19
05:18
Recommendations
Axon analyst commentary  »

Axon price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

INFO

IHS Markit

$68.90

-0.72 (-1.03%)

05:18
11/12/19
11/12
05:18
11/12/19
05:18
Conference/Events
IHS Markit to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PLNT

Planet Fitness

$67.73

-0.7 (-1.02%)

05:16
11/12/19
11/12
05:16
11/12/19
05:16
Recommendations
Planet Fitness analyst commentary  »

Planet Fitness price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

05:15
11/12/19
11/12
05:15
11/12/19
05:15
General news
Breaking General news story  »

Federal Reserve Board of…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.